Heather Gibbs, MD
Gastroenterology · Lewes, DENPI 1275895625
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 200 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 26.5% of the total. Reporting peaked in 2020 at $1,629 and has fallen 71.6% since, to $463 in 2025.
Across 200 payments — averaging $22.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Gilead$942
- Johnson & Johnson$544
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$359
- Intercept Pharmaceuticals, Inc.$234
- Takeda Pharmaceuticals U.S.A., Inc.$234
- plus $990 from 14 others
What the payments were for
- Food & beverage$4,481100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 36 | $1,189 |
| Gilead | 36 | $942 |
| Johnson & Johnson | 33 | $544 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 21 | $359 |
| Intercept Pharmaceuticals, Inc. | 7 | $234 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $234 |
| Boston Scientific | 2 | $163 |
| Pfizer | 8 | $156 |
| Redhill Biopharma Inc. | 9 | $149 |
| Ironwood Pharmaceuticals, Inc | 11 | $140 |
| Braintree Laboratories, Inc. | 5 | $95 |
| QOL Medical, LLC | 6 | $92 |
| Daiichi Sankyo Inc. | 3 | $52 |
| Madrigal Pharmaceuticals | 2 | $40 |
| Dova Pharmaceuticals | 2 | $26 |
| Shire North American Group Inc | 1 | $21 |
| Merck | 1 | $17 |
| Medtronic | 1 | $17 |
| Shionogi Inc | 1 | $12 |
| Olympus America Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mavyret$360
- WallFlex Duodenal$150
- Skyrizi$125
- OCALIVA$119
- Vemlidy$118
How this compares
$4,492 in reported general payments places this provider in the 60th percentile of 50 gastroenterology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 22 | $601,793 |
| Humira(Cf) PenAdalimumab | 34 | $286,470 |
| OcalivaObeticholic Acid | 26 | $125,050 |
| XeljanzTofacitinib Citrate | 20 | $109,676 |
| LinzessLinaclotide | 73 | $65,089 |
| XifaxanRifaximin | 12 | $60,843 |
| Dexlansoprazole DrDexlansoprazole | 93 | $36,393 |
| MotegrityPrucalopride Succinate | 21 | $19,780 |
| Opium Tincture | 18 | $16,581 |
| TrulancePlecanatide | 14 | $13,493 |
| Mesalamine | 48 | $13,052 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 197 | $12,147 |
| Mesalamine ErMesalamine | 19 | $8,120 |
| Omeprazole | 451 | $6,943 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 100 | $5,217 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $544 | $601,79322 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $234 | $125,05026 claims |
| PfizerXeljanz | $156 | $109,67620 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu | $359 | $79,32764 claims |
| AbbVieLinzess | $1,189 | $65,08973 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $234 | $19,78021 claims |
| Braintree Laboratories, Inc.Sutab | $95 | $3,13620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 50 gastroenterology providers in Delaware.
Other gastroenterology in Lewes
- Richard CarusoLewes$13K
- Srinivas RamireddyLewes$3K
- Sujay AlvencarLewes$938
- Geoffrey BradenLewes$883
- Mark WilkinsonLewes$705
- Harry AnagnostakosLewes$676
- Robert DeckmannLewes$580
- Paolo PeghiniLewes$490
- Shaina LynchLewes$129
- Michael BrooksNewark$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.